Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria

Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment

(2015) Beate Jahn et al.   MEDICAL DECISION MAKING

Systematic overview of cost–effectiveness thresholds in ten countries across four continents

(2015) Ruth Schwarzer et al.   Journal of Comparative Effectiveness Research

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis

(2014) S Ward et al.   HEALTH TECHNOLOGY ASSESSMENT

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement†

(2013) H. A. Azim et al.   ANNALS OF ONCOLOGY

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) E. Senkus et al.   ANNALS OF ONCOLOGY

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

(2013) Josh J. Carlson et al.   BREAST CANCER RESEARCH AND TREATMENT

Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility

(2013) P. Sinn et al.   GEBURTSHILFE UND FRAUENHEILKUNDE

Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer

(2013) Mike Paulden et al.   VALUE IN HEALTH

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

(2012) A. Prat et al.   ANNALS OF ONCOLOGY

Cost effectiveness of gene expression profiling for early stage breast cancer

(2012) Mo Yang et al.   CANCER

Modeling Using Discrete Event Simulation

(2012) Jonathan Karnon et al.   MEDICAL DECISION MAKING

Modeling Good Research Practices—Overview

(2012) J. Jaime Caro et al.   MEDICAL DECISION MAKING

Model Parameter Estimation and Uncertainty Analysis

(2012) Andrew H. Briggs et al.   MEDICAL DECISION MAKING

PRM16 Evaluation of Personalized Breast Cancer Test-Treatment Strategies - A Cross-Validation Study Between a Discrete-Event Simulation and a Markov Model

(2012) B. Jahn et al.   VALUE IN HEALTH

Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6

(2012) Andrew H. Briggs et al.   VALUE IN HEALTH

St. Gallen 2011: Summary of the Consensus Discussion

(2011) Michael Gnant et al.   Breast Care

Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast Cancer

(2011) Peter S. Hall et al.   JNCI-Journal of the National Cancer Institute

Physician Survey of the Effect of the 21-Gene Recurrence Score Assay Results on Treatment Recommendations for Patients With Lymph Node–Positive, Estrogen Receptor–Positive Breast Cancer

(2011) Ruth Oratz et al.   Journal of Oncology Practice

Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)

(2010) Masahide Kondo et al.   BREAST CANCER RESEARCH AND TREATMENT

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

(2010) Eleftherios P. Mamounas et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection

(2010) Shelly S. Lo et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer

(2010) D. T. Tsoi et al.   ONCOLOGIST

Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization

(2010) Shmuel H. Klang et al.   VALUE IN HEALTH

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

(2009)   GENETICS IN MEDICINE

Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

(2009) Shelby D. Reed et al.   JOURNAL OF CLINICAL ONCOLOGY

The influence of a Gene expression profile on breast cancer decisions

(2009) Leonard R. Henry et al.   JOURNAL OF SURGICAL ONCOLOGY

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

(2008) Juhi Asad et al.   AMERICAN JOURNAL OF SURGERY